Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongbin Li

Showing results (581-590 of 594) with videos related to

Pageof 60
Sort By:
RMD Open|November 23, 2023
Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosusHanxiao You, Jiuliang Zhao, Miaojia Zhang, et al.
Rheumatology (Oxford, England)|February 3, 2026
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 studyYu Xue, Lingyun Sun, Ning Zhang, et al.
Arthritis Research & Therapy|April 12, 2018
Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled studyYang-Zhong Zhou, Li-Dan Zhao, Hua Chen, et al.
Medcomm|February 19, 2025
Low versus high peripheral oxygen saturation directed oxygen therapy in critically ill patients: a multicenter randomized controlled trialXiaobo Yang, Xuehui Gao, Xiang Zheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 2024
The international empirics of managementDaniela Scur, Scott Ohlmacher, John Van Reenen, et al.
The Lancet. Rheumatology|January 17, 2024
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trialHuji Xu, Zhijun Li, Jian Wu, et al.
Eclinicalmedicine|May 4, 2026
Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trialLifan Zhang, Yujie He, Wenwen Wang, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 18, 2013
The prion protein ligand, stress-inducible phosphoprotein 1, regulates amyloid-β oligomer toxicityValeriy G Ostapchenko, Flavio H Beraldo, Amro H Mohammad, et al.
JAMA Network Open|May 8, 2026
Vunakizumab for Radiographic Axial Spondyloarthritis: A Randomized Clinical TrialJian Zhu, Cheng Zhao, Cundong Mi, et al.
Small (Weinheim an Der Bergstrasse, Germany)|January 1, 2023
An Adhesive Bioink toward Biofabrication under Wet ConditionsWanlu Li, Mian Wang, Shiwei Wang, et al.
Pageof 60

Showing results (581-590 of 594) with videos related to

Sort By:
Pageof 60
RMD Open|November 23, 2023
Development and external validation of a prediction model for venous thromboembolism in systemic lupus erythematosusHanxiao You, Jiuliang Zhao, Miaojia Zhang, et al.
Rheumatology (Oxford, England)|February 3, 2026
Vunakizumab in patients with active psoriatic arthritis: a multicentre, randomized, double-blind, placebo-controlled, phase 2 studyYu Xue, Lingyun Sun, Ning Zhang, et al.
Arthritis Research & Therapy|April 12, 2018
Comparison of the impact of Tripterygium wilfordii Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled studyYang-Zhong Zhou, Li-Dan Zhao, Hua Chen, et al.
Medcomm|February 19, 2025
Low versus high peripheral oxygen saturation directed oxygen therapy in critically ill patients: a multicenter randomized controlled trialXiaobo Yang, Xuehui Gao, Xiang Zheng, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 2024
The international empirics of managementDaniela Scur, Scott Ohlmacher, John Van Reenen, et al.
The Lancet. Rheumatology|January 17, 2024
IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trialHuji Xu, Zhijun Li, Jian Wu, et al.
Eclinicalmedicine|May 4, 2026
Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trialLifan Zhang, Yujie He, Wenwen Wang, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 18, 2013
The prion protein ligand, stress-inducible phosphoprotein 1, regulates amyloid-β oligomer toxicityValeriy G Ostapchenko, Flavio H Beraldo, Amro H Mohammad, et al.
JAMA Network Open|May 8, 2026
Vunakizumab for Radiographic Axial Spondyloarthritis: A Randomized Clinical TrialJian Zhu, Cheng Zhao, Cundong Mi, et al.
Small (Weinheim an Der Bergstrasse, Germany)|January 1, 2023
An Adhesive Bioink toward Biofabrication under Wet ConditionsWanlu Li, Mian Wang, Shiwei Wang, et al.
Pageof 60